Endocrine Abstracts (2019) 68 P23 | DOI: 10.1530/endoabs.68.P23

Effects of debulking surgery, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) on quality of life in patients with metastatic ileal and pancreatic neuroendocrine tumours (NETs)

Adam Sinclair1, Lulu Tanno2, Emma Jarvis2, Emma Ramsey2, Salma Naheed2, Thomas Armstrong2, Arjun Takhar2, John Knight2, Brian Stedman2, Sachin Modi2, Timothy Bryant2, David Breen2, Luke Nolan2, Ma’en Al-Mrayat2, Neil Pearce2 & Judith Cave2


1University of Southampton, Southampton, UK; 2University Hospital Southampton, Southampton, UK


Neuroendocrine tumours (NETs) are a heterogenous group of tumours that arise from neuroendocrine cells throughout the body. Debulking surgery is offered to patients with metastatic NETs and is recommended in the ENETS guidelines. This study was undertaken to evaluate the impact of debulking surgery and liver directed therapy (TACE, TAE) in metastatic NETs, on quality of life (QoL). Prospective longitudinal cohort study was undertaken at University Hospital Southampton. Patients who were due to receive debulking surgery, TAE or TACE were included. Validated EORTC QLQ-C30 and EQ-5D questionnaires were used at pre-op, post-op and 3 monthly intervals to assess patients’ QoL after surgery. 25 participants were recruited between October 2017 to September 2019, with 4 participants deemed ineligible. Of the remaining 21 participants 12 were female and 9 were male. The median age was 72 (range of 48–75 years). The majority were G1 (n=13 61.9%), with a further 23.8% with G2 (n=5) and 14.3% with G3 (n=3) diseases. The most common primary sites were the ileum (n=8) and pancreas (n=6). A total of 8 patients had a functioning NET. 16 patients underwent debulking surgery, 4 patients underwent TAE and 1 patient underwent TACE. 81.0% (n=17) of treatments were for liver metastases.